Thyroid eye disease (TED) is an autoimmune condition where the body’s immune system attacks the tissues around and behind the eyes, causing inflammation, swelling, and sometimes vision problems.

What is thyroid eye disease?

Thyroid eye disease (also called Graves’ eye disease, Graves’ ophthalmopathy, or Graves’ orbitopathy) happens in some people who have thyroid problems, most often Graves’ disease (an overactive thyroid), but it can also occur when thyroid levels are normal or low. In TED, immune cells and antibodies that target the thyroid also mistakenly target the muscles, fat, and soft tissues in the eye socket (orbit), leading to irritation, bulging eyes, and other eye changes. It usually affects both eyes, but one eye can look or feel worse than the other.

Key symptoms people notice

Common symptoms build gradually and can vary from mild irritation to serious eye problems.

  • Bulging or “staring” eyes (proptosis/exophthalmos).
  • Eyelid retraction (lids pulled back wider than normal) and puffy, swollen lids.
  • Red, gritty, dry, or watery eyes that feel irritated or like there is sand inside.
  • Light sensitivity and eye pain or pressure, sometimes behind the eye.
  • Difficulty moving the eyes and double vision (seeing two of one object).
  • In severe cases, blurred vision or vision loss if the swollen tissues compress the optic nerve or damage the cornea.

If someone with thyroid disease notices new eye bulging, double vision, or any vision loss, they should seek urgent medical care.

Why does TED happen?

Thyroid eye disease is an autoimmune disorder.

  • The immune system produces antibodies that target receptors shared by thyroid cells and cells in the tissues behind the eye.
  • These antibodies trigger inflammation and cause the eye muscles and fat to swell, enlarge, and sometimes become scarred and stiff over time.
  • TED most often occurs with Graves’ hyperthyroidism, but it can appear before, during, or after thyroid disease, and occasionally when thyroid hormone levels are normal (euthyroid) or low (hypothyroid).

Not everyone with Graves’ disease develops TED, but up to about half of people with Graves’ may show some eye involvement.

Who is at higher risk?

Several factors make TED more likely or more severe.

  • Smoking: the strongest known risk factor; smokers are much more likely to develop active or severe TED and to stay in the active phase longer.
  • Uncontrolled thyroid levels (over‑ or under‑active thyroid not well treated).
  • Female sex: women are affected more often, though men may have more severe disease when it occurs.
  • Middle age and certain genetic predispositions.
  • Radioactive iodine treatment for Graves’ disease can sometimes worsen or trigger TED in high‑risk patients (especially smokers), which is why eye risk is considered when choosing thyroid therapies.

Stopping smoking and keeping thyroid levels well-controlled are two of the most important modifiable steps.

How the disease typically evolves

TED usually has distinct phases.

  1. Active (inflammatory) phase
    • Symptoms “flare” and can change from week to week: more redness, swelling, eye bulging, and double vision.
 * This phase often lasts about 1–3 years, and tends to be longer and more intense in smokers.
  1. Inactive (stable) phase
    • Inflammation settles down, but the structural changes (bulging, lid position, double vision) may remain.
 * At this point, the disease is “burned out,” and doctors focus more on repair (for example, surgery), not on suppressing active inflammation.

TED can very occasionally “reactivate,” but this is less common.

Diagnosis: how doctors confirm TED

Doctors use a mix of history, eye exam, and tests to diagnose thyroid eye disease.

  • History and physical exam
    • Known thyroid disease (especially Graves’), timing of eye symptoms, smoking history, and family history.
* Eye exam checks lid position, eye movements, corneal health, eye pressure, and signs of optic nerve damage.
  • Laboratory tests
    • Blood tests to check thyroid hormone levels and thyroid antibodies.
  • Imaging
    • CT or MRI scans of the orbits to look for enlarged eye muscles and inflamed tissues behind the eye.

Often, the combination of characteristic eye changes and thyroid disease is enough for a confident diagnosis.

Treatment: what can be done?

Treatment depends on how active and how severe the disease is. There are two broad goals: control inflammation/active disease and correct long‑term changes.

1. General and supportive care

  • Achieve and maintain stable thyroid hormone levels with appropriate endocrine treatment.
  • Stop smoking; many centers consider smoking cessation as essential as any drug therapy.
  • Lubricating eye drops or ointments, cool compresses, sunglasses, and sleeping with the head elevated to reduce swelling and dryness.
  • Selenium supplements may help in mild, early TED in some regions, under medical guidance.

2. Medical therapies for active disease

For moderate to severe active TED, especially with double vision or threat to sight, stronger treatments may be used.

  • Corticosteroids (oral or high‑dose intravenous) to quickly reduce inflammation and swelling.
  • Immunomodulatory / biologic therapies to target immune pathways driving TED (for example, newer targeted drugs used under specialist supervision).
  • Orbital radiotherapy in selected patients to reduce inflammation of the tissues behind the eye.

Sight‑threatening complications like optic nerve compression or severe corneal exposure are emergencies and often need urgent high‑dose steroids and/or surgery.

3. Surgical options (usually in inactive phase)

Once inflammation has settled, surgery can help restore function and appearance.

  • Orbital decompression: removes bone/fat to create more space in the orbit and reduce eye bulging and optic nerve pressure.
  • Eye muscle (strabismus) surgery: improves alignment to reduce double vision.
  • Eyelid surgery: corrects lid retraction or closure problems, improving appearance and protecting the cornea.

Treatment is usually coordinated between an endocrinologist and an ophthalmologist, often with a subspecialist in oculoplastic or orbital surgery.

Latest news and current trends

Recent years have seen growing attention to TED in both research and patient communities.

  • Newer biologic therapies targeting specific immune pathways have been developed and studied to reduce inflammation, eye bulging, and diplopia more effectively than older treatments in some patients.
  • There is increasing emphasis on early diagnosis, multidisciplinary care, and quality‑of‑life outcomes, not just vision and eye pressure numbers.
  • Patient education campaigns highlight smoking cessation and rapid evaluation of new eye symptoms in people with thyroid disease to prevent severe, sight‑threatening complications.

Online forums and support groups often discuss real‑world experiences with treatments, surgical outcomes, insurance/coverage issues, and coping with changes in appearance, which can significantly affect mental health and self‑esteem.

Many patients describe TED not only as an eye disease, but as a “whole‑life” condition that changes how they look, how they see, and how they feel about social interactions.

When to seek help

You should contact a doctor promptly if you (or someone you know) has thyroid disease and develops:

  • New or worsening eye bulging, redness, or swelling.
  • New double vision or trouble moving the eyes.
  • Eye pain, especially with movement.
  • Any dimming of vision, blurred vision, or loss of color vision.

Emergency evaluation is crucial if there is sudden vision loss, severe eye pain, or inability to close the eyes fully.

Bottom note: Information gathered from public forums or data available on the internet and portrayed here.